Stockscreener 앱 받기
323.95
3.33%
10.45
시간 외 거래:
323.95
전일 마감가:
$313.50
열려 있는:
$315.11
하루 거래량:
579.50K
Relative Volume:
1.20
시가총액:
$9.03B
수익:
$7.46M
순이익/손실:
$-326.53M
주가수익비율:
-24.21
EPS:
-13.3803
순현금흐름:
$-282.53M
1주 성능:
-3.24%
1개월 성능:
+27.54%
6개월 성능:
+10.70%
1년 성능:
+593.98%
1일 변동 폭
$307.00
$327.61
1주일 범위
$307.00
$337.72
52주 변동 폭
$37.19
$366.52
Praxis Precision Medicines Inc Stock (PRAX) Company Profile
명칭
Praxis Precision Medicines Inc
전화
617-300-8460
주소
99 HIGH STREET, 30TH FLOOR, BOSTON
Compare PRAX vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PRAX
Praxis Precision Medicines Inc
|
323.95 | 8.74B | 7.46M | -326.53M | -282.53M | -13.38 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.94 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.59 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Praxis Precision Medicines Inc Stock (PRAX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-10 | 개시 | Raymond James | Strong Buy |
| 2026-02-24 | 개시 | Wolfe Research | Outperform |
| 2026-02-02 | 개시 | Wells Fargo | Equal Weight |
| 2025-12-15 | 재확인 | Oppenheimer | Outperform |
| 2025-11-19 | 개시 | BTIG Research | Buy |
| 2025-06-02 | 재개 | Oppenheimer | Outperform |
| 2025-05-07 | 개시 | Chardan Capital Markets | Buy |
| 2025-03-03 | 재확인 | H.C. Wainwright | Buy |
| 2025-02-11 | 개시 | Deutsche Bank | Buy |
| 2024-08-05 | 개시 | Oppenheimer | Outperform |
| 2024-06-24 | 개시 | Needham | Buy |
| 2024-06-18 | 개시 | Guggenheim | Buy |
| 2024-05-01 | 개시 | Robert W. Baird | Outperform |
| 2023-09-19 | 개시 | Truist | Buy |
| 2022-06-06 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2021-12-16 | 개시 | H.C. Wainwright | Buy |
| 2021-08-26 | 개시 | BofA Securities | Buy |
| 2021-04-26 | 개시 | William Blair | Outperform |
| 2020-11-11 | 개시 | Wedbush | Outperform |
| 2020-11-10 | 개시 | Cowen | Outperform |
| 2020-11-10 | 개시 | Evercore ISI | Outperform |
| 2020-11-10 | 개시 | Piper Sandler | Overweight |
모두보기
Praxis Precision Medicines Inc 주식(PRAX)의 최신 뉴스
Praxis Precision (PRAX) Partners with Remagine Labs for Innovati - GuruFocus
Praxis Precision Medicines and Remagine Labs Announce Strategic Collaboration to Develop Transdermal Ulixacaltamide for Essential Tremor - The Manila Times
Praxis bets on skin patch for essential tremor drug - Stock Titan
S&P 500 Futures Climb in Premarket Trading; Praxis Precision Meds, IREN Lead - Barron's
PRAX stock. Praxis Precision Medicines holds the spotlight on thin news - AD HOC NEWS
Praxis Precision Shares Rally On Price Target Hikes: Analyst Sees Upside As High As 100% For Stock - Stocktwits
Praxis Precision (NASDAQ: PRAX) replaces EY with KPMG as auditor - Stock Titan
Praxis uses inducement plan to grant 951 shares to five hires - Stock Titan
Price to sales forward of Praxis Precision Medicines, Inc. – NASDAQ:PRAX - TradingView
Enterprise value to revenue forward of Praxis Precision Medicines, Inc. – NASDAQ:PRAX - TradingView
Price to book forward of Praxis Precision Medicines, Inc. – NASDAQ:PRAX - TradingView
We Think Praxis Precision Medicines (NASDAQ:PRAX) Can Easily Afford To Drive Business Growth - Moomoo
LifeSci Capital Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Cuts Target Price to $719 - Moomoo
The Technical Signals Behind (PRAX) That Institutions Follow - Stock Traders Daily
Guggenheim Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $800 - Moomoo
Praxis sees encephalopathies asset relutrigine action date extended - MSN
PRAX Maintained by Needham -- Price Target Raised to $575 - GuruFocus
Price to earnings forward of Praxis Precision Medicines, Inc. – NASDAQ:PRAX - TradingView
Praxis Precision Medicines (PRAX) Surges Nearly 7% as Momentum BuildsVolatility Stop - dars.gov.et
Stocks to Watch: AeroVironment, Concentrix, Gain Therapeutics, Praxis Precision Medicines - Moomoo
Praxis Precision Medicines stock falls on FDA review delay By Investing.com - Investing.com South Africa
FDA Extends Review Timeline for Praxis’ Relutrigine NDA - TipRanks
Praxis Precision Medicines stock falls on FDA review delay - Investing.com UK
FDA extends Praxis (NASDAQ: PRAX) relutrigine review deadline to Dec 27, 2026 - Stock Titan
Praxis Precision Medicines Announces FDA Extends Review of Relutrigine NDA to December 27, 2026 - Quiver Quantitative
FDA delays Praxis relutrigine review by three months to Dec. 27 - Stock Titan
Praxis Precision Medicines, Inc.(NasdaqGS:PRAX) dropped from Russell Microcap Growth Benchmark Index - marketscreener.com
Praxis Precision Medicines, Inc.(NasdaqGS:PRAX) dropped from Russell Small Cap Comp Value Benchmark - marketscreener.com
Praxis Precision Medicines, Inc.(NasdaqGS: PRAX) dropped from Russell 3000E Index - marketscreener.com
Praxis Precision Medicines, Inc.(NasdaqGS:PRAX) dropped from Russell 3000E Growth Benchmark - marketscreener.com
Praxis Precision Medicines, Inc.(NasdaqGS:PRAX) dropped from Russell 3000 Value Benchmark - marketscreener.com
Praxis Precision Medicines, Inc.(NasdaqGS: PRAX) dropped from Russell Microcap Index - marketscreener.com
Praxis Precision Medicines, Inc.(NasdaqGS:PRAX) dropped from Russell 3000E Value Benchmark - marketscreener.com
Praxis Precision Medicines, Inc.(NasdaqGS:PRAX) dropped from Russell Microcap Value Benchmark Index - marketscreener.com
Praxis gains FDA breakthrough therapy status for elsunersen for encephalopathy - MSN
Praxis Precision Medicines director Jill DeSimone sells $3.6m in shares - Investing.com Nigeria
Praxis Precision Medicines(PRAX.US) Director Sells US$3.61 Million in Common Stock - Moomoo
Form 4 Praxis Precision Medicines Inc For: 26 June By Investing.com - Investing.com South Africa
Praxis Precision Medicines Insider Sold Shares Worth $3,611,335, According to a Recent SEC Filing - marketscreener.com
Praxis (PRAX) director logs 11,600-share sale after option exercises - Stock Titan
Praxis Precision Medicines Stock Surges 27%, With A 6-Day Winning Spree - Trefis
null - Trefis
Praxis Precision Medicines, Inc. Actuals & Estimates (BOATS:PRAX) - TradingView
Praxis Precision Medicines outlines next steps, shares trade quietly on Nasdaq - Ad-hoc-news.de
PRAX Forecast — Price Target — Prediction for 2027 - TradingView
Praxis Precision Medicines, Inc. (PRAX) Stock Price, Quote, News & Analysis - Seeking Alpha
Form 144 Praxis Precision Medicines For: 24 June By Investing.com - Investing.com Australia
Form 144 | Praxis Precision Medicines(PRAX.US) Director Proposes to Sell 3.61 Million in Common Stocks - Moomoo
[144] Praxis Precision Medicines, Inc. SEC Filing - Stock Titan
Praxis Precision Medicines (PRAX): Best Upside Stocks to Buy According to Hedge Funds - Insider Monkey
Praxis 'Strong Buy': PDUFA In Early 2027 For Ulixacaltamide And BTD Elsunersen (PRAX) - Seeking Alpha
Praxis Precision Medicines Inc (PRAX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Praxis Precision Medicines Inc 주식 (PRAX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| DeSimone Jill | Director |
Jun 24 '26 |
Sale |
311.32 |
11,600 |
3,611,335 |
2,337 |
1.17%
2.48%
자본화:
|
볼륨(24시간):